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A-type gamma-aminobutyric acid receptors 
(GABAA receptors or GABAARs) are hetero-
oligomeric complexes which form chloride-
permeable ion channels. GABAARs represent 
major fast inhibitory receptors in the central 
nervous system (CNS). Distinct isoforms of GAB-
AARs have different pharmacological, develop-
mental, and physiological feature and are local-
ized to specific cellular compartments [1, 2]. 
The binding of GABA to its ionic receptors 
causes a change of conformation that permits 
the influx/efflux of chloride ions which, in adult 
neurons, shunt excitatory input and render neu-
rons less excitable [1]. Generally, enhancing 
GABAAR activities by agents such as sedatives, 
or general anaesthetics ‘soothes’ the brain [3], 
while blocking GABAARs with GABA antagonists 
disinhibits and excites the nervous system. 
However, GABAA receptors also distribute to non
-neuronal tissues such as liver, lung and pan-
creas [4-7], participating in a variety of func-
tions such as secretion and fluid balance. For 
example, GABAergic system has been recently 
characterized in airway epithelia of the lung [4, 
6, 8]. Activation of GABAA receptors in lung, in 
contrast to the brain, leads to depolarization of 
lung airway cells facilitating epithelial secretion 
[6]. In addition, GABAARs are responsible for 
mucus overproduction and the activation of 
GABAAR promotes asthma [6]. Conversely, 
blockade of GABAARs by GABA antagonists pre-
vents mucus secretion. These findings implicate 
that airway GABAARs may serve as novel targets 
for treating asthma [9]. However, due to their 
CNS effect, most antagonists of GABAAR are pro-
convulsive, which limits their therapeutic poten-
tial in combating GABAAR-associated disorders 
in non-neuronal tissues [10-13].  
 
Futhan (FUT-175, or Nafamostat Mesylate, 
chemical name: 6-Amidino-2-naphthyl-4-guanidi-
nobenzobate dimethanesulfonate) is a syn-
thetic, competitive, reversible serine protease 
inhibitor and has potent inhibition on a wide 
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Abstract: Futhan is a serine protease inhibitor and medicine in the treatment of disseminated intravascular coagula-
tion (DIC) and acute pancreatitis. It is metabolized quickly in vivo. Here we show that Futhan reversibly inhibits NMDA 
receptors in hippocampal neurons and GABAA receptors both in hippocampal neurons and in A549 cells, a human 
alveolar epithelial cell line. The effect of Futhan on GABAA receptors in A549 cells is much more potent than its effect 
on GABAA receptors in hippocampal neurons (IC50: 0.9 µM v.s. 7.3 µM). Since GABAA receptors are also expressed in 
various non-neuronal tissues, particularly in airway epithelia and GABA promotes mucus production during asthma, 
our findings indicate that Futhan may be developed as a novel aerosolized therapeutic to treat asthma through block-
ing GABAA receptors in the lung.  
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spectrum of proteases, including trypsin, throm-
bin, plasmin, kallikreins, factors B and D, factor 
Xa, and tryptase [14-18]. This inhibitory spec-
trum confers Futhan capacity to intervene the 
coagulation-fibrinolysis system, the kallikrein-
kinin system and the complement system. 
Therefore Futhan functions as an anti-
inflammation and anti-coagulation agent [14, 
19, 20]. Futhan is clinically used for the treat-
ment of DIC and acute pancreatitis and also 
serves as an anticoagulant agent in extracorpo-
real circulation (ECC) [19-21].  
 
As for its chemical structure, Futhan is a highly 
polarized, di-cationic agent governed by an 
amidine group at one end and a guanidine 
group at the other [15]. It is highly hydrophilic 
and cannot readily penetrate the BBB to enter 
the brain [14, 15]. Moreover, Futhan is an un-
stable drug as an ester conjugate of 6-amidino-
2-naphthol (AN) and p-guanidinobenzoic acid (p-
GBA).   It can be rapidly hydrolyzed into AN and 
p-GBA in vivo by esterase in the liver and blood 
[14]. 
 
Accumulating evidence suggests that besides 
conventional clinical usage, Futhan also demon-
strates a myriad of other beneficial pharmacol-
ogical activities, such as anti-tumor [22, 23], 
pain relief [24], organ protection [21, 25]. Some 
effect such as anti-cancer application is being 
tested under human clinical trials [23]. More-
over, Futhan has been shown to have anti-
asthma effect in mice model [26, 27]. The phar-
macological profiles of Futhan, however, need 
to be clearly elucidated in order to avoid its ad-
verse effects and fully explore its clinical poten-
tial.  
 
Here we show that Futhan reversibly and com-
pletely inhibits both NMDA receptors and GABAA 
receptors in primarily cultured hippocampal 
neurons. In addition, Futhan more potently 
blocks GABAA receptors endogenously ex-
pressed in A549, a human alveolar epithelial 
cell line. As Futhan does not readily cross the 
blood-brain-barrier (BBB) and is metabolized 
rapidly in vivo, it may be developed into a novel 
medicine for treating asthma. 
 




Fura-2 fluorescent Ca2+ imaging was performed 
as described previously [35].  Cortical or hippo-
campal neurons grown on 25 mm round glass 
coverslips were washed three times with ECF 
and incubated with 5 µM Fura-2-AM for ~ 40 
min at room temperature.  Neurons were then 
washed three times and incubated in normal 
ECF for 30 min.  Coverslips with Fura-2-loaded 
neurons were transferred to a perfusion cham-
ber on the stage of an inverted microscope 
(Nikon TE300).  Cells were illuminated using a 
xenon lamp (75W) and observed with a 40 x UV 
fluor oil-immersion objective lens. Video images 
were obtained using a cooled CCD camera 
(Sensys KAF 1401, Photometrics, Tucson, AZ).  
Digitized images were acquired, stored, and 
analyzed in a PC controlled by Axon Imaging 
Workbench software (AIW2.1, Axon Instruments, 
Sunnyvale, CA). The shutter and filter wheel 
(Lambda 10-2, Sutter Instrument, Novato, CA) 
were also controlled by AIW to allow timed illu-
mination of cells at 340 and 380 nm excitation 
wavelengths. Fura-2 fluorescence was detected 
at an emission wavelength of 510 nm. Ratio 
images of 340/380 nm were analyzed by aver-
aging pixel ratio values in circumscribed regions 
of cells in the field of view.  The values were 
exported from AIW to SigmaPlot for further 




All animal experiments were carried out accord-
ing to guidelines approved by the University of 
Toronto Animal Care Committee. Primary cul-
tures of mouse hippocampal and cortical neu-
rons were prepared as previously described[28]. 
Electrophysiological recordings were made from 
cultured A549 cells or cultured mouse hippo-
campal neurons, 14–21 days after plating. The 
extracellular solution (ECS) was composed of (in 
mM): 140 NaCl, 2 CaCl2, 1 MgCl2 25 N-2-
Hydroxyethylpiperazine-N’-thanesulfonic acid 
(HEPES), 33 glucose, 5.4 KCl and 0.0002 tetro-
dotoxin with pH of 7.3-7.4 and osmolarity rang-
ing from 320-330 mOsm. To record NMDA-
receptor-mediated current, magnesium was not 
added in ECS. The intracellular solution for volt-
age clamp recording consisted of (in mM):140 
CsF (or 140 CsCl where indicated), 11 ethylene-
glycol-bis-(α-amino-ethyl ether) N,N’-tetra-acetic 
acid (EGTA) as intracellular calcium chelating 
buffer, 10 HEPES, 2 MgCl2, 2 tetraethyl ammo-
nium chloride (TEA-Cl), 1 CaCl2, and 4 K2ATP. 
Pipette resistance ranges were 2-4 MW when 
filled with this intracellular solution. All re-
cordings were performed at room temperature. 
Membrane potential was held at -60 mV 
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throughout the recording if not otherwise indi-
cated. Access resistance was monitored by ap-
plying a voltage step of -5 mV. GABAA (or NMDA) 
receptor - mediated current was elicited by 
rapid application of GABA (or NMDA) delivered 
from a multi-barrelled fast perfusion system for 
5 seconds and repeated every minute. AMPA 
receptors-mediated current in hippocampal neu-
rons is elicited by application of 50 µM gluta-
mate at the presence of 50 µM D-APV so as to 
block NMDA receptors. The perfusion rate of the 
solution was approximately 1 ml per minute.  
Whole-cell currents were recorded using an 
Axopatch-1D amplifier (Molecular Devices, 
Sunnyvale, CA). Electrophysiological recordings 
were filtered at 2 kHz and digitized at 5-10 kHz 
using a Digidata 1332A or/and simultaneously 
through MiniDigi 1A, and acquired online with 
pClamp8.2 (Axon Instruments) or/and Axoscope 
9.2 (Axon instruments). GABA-induced currents 
in cultured A549 cells were recorded similarly 




Data were analyzed with Clampfit 9.2 (Axon In-
struments, Sunnyvale, CA), Excel 2002 
(Microsoft Corporation, Seattle, WA, USA), Origin 
5.0 (Microcal Software, Northampton, MA) and 
final illustrated using CorelDraw13 (Corel Corpo-
ration, Mountain View, CA).  Currents were nor-
malized to the amplitude of control responses.  
NM inhibitory concentration-response plots was 
fitted to the logistic equation: I = (Amax-A0)/[1+
(X/IC50)n]+A0, where I is the normalized current 
amplitude, X is the antagonist concentration; n 
is Hill coefficient; IC50 is the concentration of 
antagonist that generate 50% of maximal inhibi-
tion. Data were presented as mean ± SEM. Fu-
than was purchased from BioMol (Plymouth 
meeting, PA, USA) and its metabolites p-GBA 




Futhan strongly blocks NMDA receptors in hip-
pocampal neurons  
        
To test if Futhan blocks some key neuronal re-
ceptors in the brain, we first used calcium-
imaging technique to monitor calcium entry 
upon NMDA challenge in primarily cultured hip-
pocampal neurons. As shown in Figure 1A, 
NMDA-induced increase of [Ca2+]i was inhibited 
by Futhan in cultured neurons.  The 340/380 
ratio was 7.04 ± 2.31 in the absence of Futhan, 
Figure 1. Futhan abolishes 
NMDA-induced calcium influx 
and blocks NMDA receptors in 
hippocampal neurons. A, calcium 
imaging. Effect of Futhan on 
NMDA-induced increase of intra-
cellular Ca2+ in cultured mouse 
hippocampal neurons. Left, rep-
resentative changes in 340/380 
nm ratio by perfusion of 100 µM 
NMDA in the absence and pres-
ence of 50 µM Futhan. Right, 
summary data showing the re-
duction of increase of 340/380 
nm ratio by Futhan, n = 9, ** 
p<0.01. B, Futhan directly blocks 
NMDA receptor in cultured hip-
pocampal neurons. Left, exam-
plar traces of NMDA evoked-
current blocked by Futhan. Bath 
and testing solution contained 
no added magnesium. Right, 
concentration response of Fu-
than blockade on NMDA recep-
tors; IC50: 1.0 ± 0.1 µM, n = 6. 
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0.08 ± 0.02 in the presence of 50 µM Futhan (n 
= 9, p < 0.01), 5.20 ± 1.44 after washout of 
Futhan, respectively, suggesting that Futhan 
inhibits NMDA receptors. Next we used whole-
cell voltage clamp to verify if Futhan affects 
NDMA receptor-mediated currents. Indeed Fu-
than inhibits NMDA currents in cultured hippo-
campal neurons (Figure 1B). It reversibly blocks 
NMDA-current in a concentration-dependent 
manner and the IC50 is 1.0 ± 0.1 µM (n = 6).  
 
Futhan blocks GABAARs in cultured hippocam-
pal neurons 
 
Next we examined whether Futhan inhibits 
GABAA receptors in cultured hippocampal neu-
rons. Figure 2A shows that Futhan (100 µM) 
reversibly and completely blocks GABAA recep-
tors. The inhibition was concentration-
dependent and the IC50 was 7.3 ± 0.6 µM (n = 
7, Figure 2B), indicating that GABAA receptors 
are also targets of Futhan.  Futhan is a linear di-
cationic ester conjugate represented by AN and 
p-GBA [29].  AN and p-GBA are two metabolites 
of Futhan in vivo [30].  Next we tested whether 
these metabolites retain Futhan’s effects in 
blocking GABAA receptors in the hippocampal 
neurons. Figure 2C and 2D show that AN and p-
GBA only weakly and reversibly blocks GABAA 
receptors in hippocampal neurons. AN blocks 
GABAARs with an IC50 of 335 µM and p-GBA 
blocks it with an IC50 of 236 µM. The weaker 
effects of AN and p-GBA on GABAA receptors 
suggest that the whole structure of Futhan is 
essential for retaining the potent inhibition on 
GABAA receptors.      
  
Futhan potently inhibits GABAA receptors ex-
pressed in lung A549 cells 
 
GABAA receptors are also expressed in periph-
eral tissues such as lung [4, 6], pancreas [7, 
31], and liver [5]. For example, GABAergic sys-
tem was recently characterized in lung airway 
Figure 2. Futhan reversibly blocks GABAA 
receptors in cultured hippocampal neu-
rons. A, Futhan reversibly and completely 
blocks GABAA receptors. Representative 
traces of GABA-activated current blocked 
by Futhan (100 µM), n = 6. B, concentra-
tion response of Futhan blockade on 
GABAA receptors, GABA-currents at the 
presence of Futhan were normalized to 
control GABA-response before Futhan 
application. C and D, AN and p-GBA 
weakly blocks GABAA receptors in hippo-
campal neurons. C, concentration re-
sponse of p-GBA blockade on GABAA 
receptors; IC50: 335 ± 40 µM, n = 5. D, 
concentration response of AN blockade 
on GABAA receptors; IC50:236 ± 47 µM, n 
= 4.   
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and alveolar epithelial cells [4, 8].  It has been 
shown that GABA promotes mucus production 
[6]. GABAA receptors expressed in peripheral 
tissues differ from neuronal GABAA receptors in 
many aspects including expression level, cur-
rent kinetics, agonist affinity and pharmacology 
[6, 9]. Therefore, we compared GABA-evoked 
current in cultured hippocampal neurons with 
that in A549, a cell line derived from lung type II 
alveolar cell. Figure 3A shows typical GABA-
currents recorded from hippocampal neurons 
and A549 cells.  Under the same recording con-
ditions, the peak current amplitude of GABA in 
neurons is 18-folds higher than that in A549 
cells. Moreover, GABA-current in A549 cells 
demonstrates only very weak desensitization 
while GABA-evoked current in neurons desensi-
tizes much faster. The ratio of steady-state cur-
rent amplitude to peak current amplitude is 
0.66 ± 0.02 (n = 23) in A549 cells, significantly 
higher than that recorded in hippocampal neu-
rons (0.27 ± 0.02, n = 23). These data confirm 
that GABAA receptor subunit composition in lung 
cells is distinct from that in hippocampal neu-
rons, suggesting that their pharmacology may 
differ too.  
 
It has been shown that Futhan has anti-asthma 
effect [26] [27]. To test if anti-asthma effect of 
Futhan is probably mediated through its anti-
GABAergic effect in the lung, we examined if 
Futhan inhibits GABAA receptors endogenously 
expressed in A549 cells. Figure 3B shows that 
Futhan blocks GABAA receptors expressed in 
A549. Futhan (10 μM) completely abolished the 
GABA-current that fully recovered after washout. 
At this concentration, Futhan only blocks ~ 40% 
GABA-current in hippocampal neurons (Figure 
2B). The IC50 of blockade on GABAA receptors of 
A549 was 0.9 μM (Figure 3C), indicating that 
the inhibition of Futhan on non-neuronal GAB-
AARs is much more potent than that of neuronal 
GABAARs. These data suggest that the anti-
asthma effect of Futhan could be partially ex-





Futhan inhibits a number of serine proteases 
[15, 16, 18].  It is clinically used to treat DIC, 
ECC and acute pancreatitis [14]. In this study, 
we report novel off-target effects of this medici-
nal compound: Futhan strongly blocks both 
GABAA receptors and NMDA receptors in cul-
Figure 3. Futhan potently blocks GABAA receptors 
endogenously expressed in A549 cells. A. Top, repre-
sentative GABA response in cultured hippocampal 
neurons (left) and in lung A549 cells (right). Intracel-
lular pipette solution was filled with 140 mM CsCl 
and other components (see methods). The peak 
amplitude of GABA-currents were 4.0 ± 0.7 nA in 
hippocampal neurons (n = 9) and 0.22 ± 0.04 nA in 
A549 cells (n = 23). Bottom, bar graph shows ratio of 
steady-state current to peak current amplitude (S-s/
peak) in neurons and in A549 cells, respectively. 
GABA-current in A549 desensitized less strongly than 
in neurons. ** p<0.01. B, representative GABA-
current trace recorded from A549 cells; Futhan (10 
µM) reversibly and completely abolished the re-
sponse evoked by GABA, n = 6.  C, concentration 
response of Futhan blockade on GABAA receptors in 
A549 cells. Left, current trace representative (scaled 
and superimposed), various concentrations of Fu-
than were mid-applied, indicated by empty bar. 
Right, concentration response of Futhan inhibition, 
IC50:0.9 ± 0.1 µM, n = 7.   
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tured hippocampal neurons. Interestingly, Fu-
than preferentially blocks GABAA receptors ex-
pressed in lung epithelial cells.  
 
Although Futhan blocks acid-sensing ion chan-
nels [32-34], TRPM7 [35], NMDA receptors, 
AMPA receptors ( with an IC50 of 321 ± 49 µM, 
unpublished) and GABAA receptors that are criti-
cal for neuronal functions, so far there are no 
reports to demonstrate obvious pro-convulsive 
effects or other neurological complications of 
this drug [14]. This is probably due to several 
facts. First, Futhan is a double-charged chemi-
cal, making it very difficult to enter the brain to 
encounter these neuronal receptors. Secondly, 
Futhan is metabolized rapidly in the body [36, 
37]. The system retention time of Futhan is very 
short (5~8 min after hemodialysis) [14], which 
decrease its effective concentration in vivo. 
Thirdly, Futhan is the only active form and its 
molecular integrity appears to be essential for 
retaining its anti-protease activities [14]. Simi-
larly, our data demonstrates that Futhan’s me-
tabolites p-GBA and AN only affect GABAA recep-
tors weakly. Fourthly, the potency of Futhan on 
lung GABAA receptors is ~ 8-fold higher than on 
neuronal receptors. These features largely ex-
plain why Futhan remains as a relatively safe 
medicine even if Futhan strongly blocks NMDA 
receptors and GABAA receptors in neurons. On 
the other hand, as Futhan can effectively target 
GABAA receptors that are distributed to periph-
eral non-neuronal tissues, this may partly ac-
count for its beneficial effects. Indeed GABAA 
receptors are widely expressed in non-neuronal 
tissues such as lung [4, 6], pancreas [7, 31], 
and liver [5], participating in a plethora of 
(patho-)physiological functions like asthma [6], 
diabetes [12, 13], hepatic encephalopathy and 
systemic hypotension [5]. In this regard, Futhan 
could exert its beneficiary impacts in vivo 
through targeting GABAA receptors.  
 
Our study indeed suggests that Futhan may be 
a good drug candidate to intervene diseases 
involving non-neuronal GABAergic system such 
as asthma [6] through a combination of its anti-
GABAergic and anti-protease properties. Futhan 
protects lung from various insults [38, 39]. 
Moreover, Futhan inhibits airway eosinophilic 
inflammation and airway epithelial remodeling 
in a murine model of allergic asthma [26]. In 
line with this finding, Futhan attenuates allergen
-induced airway inflammation and eosinophilia 
[27]. But these studies have not clearly defined 
which mechanism contributes to the anti-
asthma effect of Futhan [40]. We found that 
Futhan potently blocks GABAA receptors ex-
pressed in lung cells. As activation of GABAARs 
promotes mucus secretion during asthma [6], 
Futhan (aerosolized or intravenously adminis-
tered) can be developed to combat asthma 
through blocking GABAergic system in the air-
way. 
 
Cells in different tissues have different chloride 
reversal potentials, controlled by distinct chlo-
ride transporters [41, 42], which accounts for 
diverse and even opposite functions of GABAARs 
at different locations. Generally in the nervous 
system, GABA dampens neuronal excitation in 
adults and GABA-potentiating agents such as 
sedatives, narcotics, and general anaesthetics 
are widely used for therapeutic purposes [3, 43-
45]. Conversely GABAA receptor-blocking agents 
often have harmful or pro-convulsive effects. 
However, in non-neuronal tissues, activation of 
GABAA receptors tends to increase cellular ac-
tivities [6, 8]. This study indicates that Futhan 
can be developed as a novel medicine for non-
neuronal GABA-associated diseases, like 
asthma, because it can preferentially target non
-neuronal GABAA receptors and largely restrict 
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